Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
A relatively small but growing number of drug developers are monetizing their royalties/revenues by selling off all or part of these income streams to investors. If done prior to launch, these deals can protect against downside risk of the product not being a commercial success. But royalty/revenue monetization is still a relatively expensive source of capital, compared to raising conventional debt, if that is a possibility. Click here for more pros and cons. The amount of capital provided for royalty/revenue monetization deals over the past five years has doubled since between 2000 and 2005. Tell us if you would tap into this source of capital.